I expect a trend reversal once we hit the 200 EMA (golden line on bottom) with a slow climb back up. I am labeling this as a Long because it is bearish only for short term. The Stoch RSI has more room to move towards the oversold side but it should not be for more than a day, two max. I expect us to reverse trend from there and move on up with resistance close to...
INO is sitting right at support. Excellent entry point with at least 50% upside min in the short term. My target is 24.36 --- let's do this!!!
INO forming what seems to be a head and shoulders. Here is why I'm neutral on this: Even though, Head and Shoulders is spotted, it has not break below the neckline for downward momentum. If it bounces off the neckline and breaks out of the descending trendline, then a downtrend would be invalidated and bulls would take over for that scenario. Be on the look out...
Adam and eve pattern+ Exponential growth+ Measured move
Great buying opportunity, with a excellent chance to break out of bull flag. A conservative trader would wait for the breakout, but I like the setup now near fib line. Give me your thoughts
Been watching this chart for 2 weeks now and finally testing support upwards channel which should happen within couple weeks. If hold great entry position to move to its resistance Trendline. Not Financial Adviser Bla Bla ...but like if you Agree Thanks!
mostly retail interest in this company that has no approved vaccines to date.
see full chart at www.tradingview.com AZN Entry $54 area Target $57 stoploss 53 Why this play? Covid Vaccine stocks are hot right now, cases are rising = easy money. What is AZN? AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection,...
Looks like INO is coming in for a dip buy opportunity!. A round and even number like $20 per share is still a good deal IMO>
As you can see in this chart you will see my outline of the Support and Resistance line up, We are looking for a break out reversal between 26 and 27 the Goal is this company should buy at price of 27 to reach 30 Depending on the Positive Data Vaccine with Phase 3 . Goodluck Everyone and stay safe.
$VBIV continues to amaze. Just when you think the run is over trader propel this stock higher. Following the old adage - "don't fight the trend" we see VBIV continuing to rise into earnings Aug 3 with brief profit taking along the way. Day traders paradise. Longer term...we're talking weeks...expect VBIV to bask in the glow of being the only self described pan...
see full chart at www.tradingview.com AZN Entry $51.68 Target $53 stoploss $50 Why this play? they are really trying to push the Covid wave 2 case, and the market is crash. so if wave 2 really comes, these stocks should pump even further. What is AZN? AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology,...
Looking at the trends and the candle sticks, I think INO is going up for the coming weeks/months. However, all very much depending on the outcome of the ongoing clinical trial: some results leaked and these were moderately positive (clinicaltrials.gov and www.pharmaceutical-technology.com). If the final results are disappointing or negative, it will go down,...
All it will take is a little positive news to sent $INO to new 52 week highs. Lots of news potential in July. Support in low 20s confirmed. MACD about to go green, trend is up. Establish call option position here and add on the way up.
As you can see from the simple chart below. INO appears to be back on its path of growth it was on before it went Parabolic on the news that the DoD was buying $70m worth of Inovio vaccine injectors. They are submitting their Phase I trial data to peer reviewed journals (as it always does) on Monday. None of the other vaccine candidates in Operation Warp Speed...
INO has been one of the real poster-boys for the so-called Robinhood bubble. The company is a chronic underperformer in the biotech space with a likely failed vaccine candidate -- given its lack of detail in any update -- powering the action despite the fact that vaccines generally aren't profitable in the first place, and this isn't going to be it. Caution!